Comparative Pharmacology
Head-to-head clinical analysis: TIGAN versus TORECAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TIGAN versus TORECAN.
TIGAN vs TORECAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
TIGAN (trimethobenzamide) acts on the chemoreceptor trigger zone (CTZ) to inhibit emetic stimuli, primarily through antagonism of dopamine D2 receptors, though its exact mechanism is not fully elucidated.
TORECAN (thiethylperazine) is a phenothiazine derivative that acts primarily as a dopamine D2 receptor antagonist in the chemoreceptor trigger zone (CTZ) to exert antiemetic effects. It also possesses anticholinergic and antihistaminergic properties.
Adults: 200 mg IM or 100 mg PO or 200 mg PR every 6–8 hours as needed.
10 mg orally or intramuscularly every 6 to 8 hours as needed for nausea and vomiting.
None Documented
None Documented
12-15 hours; may be prolonged in hepatic impairment.
Terminal elimination half-life: 6-8 hours. Clinical context: Allows twice-daily dosing; prolonged in renal impairment.
Renal (30-50% as unchanged drug and metabolites), biliary/fecal (minor).
Primarily renal (60-70% as unchanged drug and metabolites); biliary/fecal (20-30%).
Category C
Category C
Antiemetic
Antiemetic